PL3434669T3 - Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich - Google Patents

Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich

Info

Publication number
PL3434669T3
PL3434669T3 PL18188873T PL18188873T PL3434669T3 PL 3434669 T3 PL3434669 T3 PL 3434669T3 PL 18188873 T PL18188873 T PL 18188873T PL 18188873 T PL18188873 T PL 18188873T PL 3434669 T3 PL3434669 T3 PL 3434669T3
Authority
PL
Poland
Prior art keywords
intermediate compounds
huperzine
synthesis
utilizable
compounds utilizable
Prior art date
Application number
PL18188873T
Other languages
English (en)
Inventor
Seth HERZON
Maung Kway Moe Tun
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of PL3434669T3 publication Critical patent/PL3434669T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
PL18188873T 2011-03-04 2012-02-17 Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich PL3434669T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161449198P 2011-03-04 2011-03-04
EP12755750.2A EP2681199B1 (en) 2011-03-04 2012-02-17 Process for the preparation of (-)-huperzine a
PCT/US2012/025628 WO2012121863A1 (en) 2011-03-04 2012-02-17 (--)- huperzine a processes and related compositions and methods of treatment
EP18188873.6A EP3434669B1 (en) 2011-03-04 2012-02-17 Intermediate compounds utilizable in synthesis of (-) huperzine and process for obtain one of these intermediate compounds

Publications (1)

Publication Number Publication Date
PL3434669T3 true PL3434669T3 (pl) 2021-05-31

Family

ID=46798513

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12755750T PL2681199T3 (pl) 2011-03-04 2012-02-17 Sposób wytwarzania (-)-hupercyny A
PL18188873T PL3434669T3 (pl) 2011-03-04 2012-02-17 Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12755750T PL2681199T3 (pl) 2011-03-04 2012-02-17 Sposób wytwarzania (-)-hupercyny A

Country Status (11)

Country Link
US (5) US10059672B2 (pl)
EP (2) EP3434669B1 (pl)
JP (2) JP5922157B2 (pl)
KR (1) KR102017123B1 (pl)
CN (2) CN106117140B (pl)
AU (2) AU2012226251B2 (pl)
CA (1) CA2829026C (pl)
ES (2) ES2701730T3 (pl)
MX (1) MX346339B (pl)
PL (2) PL2681199T3 (pl)
WO (1) WO2012121863A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287249B2 (en) * 2014-10-03 2019-05-14 Amphastar Pharmaceuticals, Inc. Methods of resolving racemic mixture to obtain (−)-huperzine A
US20180333365A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
CN109200051A (zh) * 2017-07-03 2019-01-15 南京和博生物医药有限公司 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
JP7566661B2 (ja) 2021-02-22 2024-10-15 株式会社ニッセイ 差動減速機
CN114702391B (zh) * 2021-12-17 2024-09-03 青岛科技大学 一种利用双氧水进行霍夫曼重排制环丙胺的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
USRE38460E1 (en) 1994-12-28 2004-03-09 Shanghai Institute Of Materia Medica Chinese Academy Of Sciences Huperzine A derivatives, their preparation and their use
CN1052225C (zh) * 1994-12-28 2000-05-10 中国科学院上海药物研究所 石杉碱甲衍生物,其制备方法和用途
JPH0995483A (ja) * 1995-07-27 1997-04-08 Sagami Chem Res Center (11E)−5−アミノ−11−エチリデン−5,6,9,10−テトラヒドロ−7−メチル−5,9−メタノシクロオクタ[b]ピリジン−2(1H)−オン誘導体およびその製造中間体
JPH1036352A (ja) * 1996-07-23 1998-02-10 Sagami Chem Res Center (11E)−5−アミノ−11−エチリデン−5,6,9,10−テトラヒドロ−5,9−メタノシクロオクタ[b]ピリジン−2(1H)−オン誘導体およびその製造中間体
AU8925998A (en) 1997-09-03 1999-03-22 Macro Hi-Tech Jv, Ltd. Huperzine a derivatives
US6271397B1 (en) 1998-06-05 2001-08-07 Showa Denko Kabushiki Kaisha L-ascorbic acid-2-phosphoric acid potassium crystal and method for producing the same
US6271379B1 (en) * 2000-03-08 2001-08-07 Georgetown University Intermediates useful for the synthesis of huperzine A
EP1300396B1 (en) 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
CA2609612C (en) * 2005-05-23 2014-09-23 President & Fellows Of Harvard College Use of huperzine to treat epilepsy
CN101130520B (zh) * 2006-08-24 2010-05-12 中国科学院上海药物研究所 经非对映异构体盐的外消旋体拆分制备天然(-)-石杉碱甲和非天然(+)-石杉碱甲的新方法
CN100528844C (zh) * 2007-04-20 2009-08-19 中国科学院昆明植物研究所 石杉碱甲衍生物,其制备方法和其应用
US20090247754A1 (en) * 2008-03-25 2009-10-01 Debiopharm S.A. Method of preparing huperzine a and derivatives thereof

Also Published As

Publication number Publication date
US10059672B2 (en) 2018-08-28
US10457643B2 (en) 2019-10-29
AU2012226251B2 (en) 2017-05-04
CA2829026A1 (en) 2012-09-13
US20200392086A1 (en) 2020-12-17
MX2013010025A (es) 2014-03-27
CN106117140B (zh) 2020-05-05
PL2681199T3 (pl) 2019-03-29
AU2017204748B2 (en) 2019-06-20
EP3434669B1 (en) 2020-11-04
CN106117140A (zh) 2016-11-16
ES2701730T3 (es) 2019-02-25
JP2016185949A (ja) 2016-10-27
AU2012226251A1 (en) 2013-10-17
JP6200996B2 (ja) 2017-09-20
EP2681199A4 (en) 2014-08-06
US20200109118A1 (en) 2020-04-09
EP3434669A1 (en) 2019-01-30
CN103687849A (zh) 2014-03-26
MX346339B (es) 2017-03-15
WO2012121863A1 (en) 2012-09-13
EP2681199B1 (en) 2018-09-26
KR102017123B1 (ko) 2019-09-02
US20220064123A1 (en) 2022-03-03
CA2829026C (en) 2020-08-11
EP2681199A1 (en) 2014-01-08
KR20140009444A (ko) 2014-01-22
AU2017204748A1 (en) 2017-07-27
CN103687849B (zh) 2016-08-17
US20180237395A1 (en) 2018-08-23
US20150158817A1 (en) 2015-06-11
JP2014508777A (ja) 2014-04-10
ES2847229T3 (es) 2021-08-02
JP5922157B2 (ja) 2016-05-24
US11142503B2 (en) 2021-10-12
US10781179B2 (en) 2020-09-22

Similar Documents

Publication Publication Date Title
EP2794907A4 (en) METHODS AND MATERIALS FOR EVALUATING LOSS OF HETEROZYGOTIA
EP2667714A4 (en) METHOD OF PREPARING 4-AMINO-5-FLUORO-3-HALO-6- (SUBSTITUTE) PICOLINATES
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
ZA201208151B (en) Methods for improving quality of sleep
HK1199245A1 (en) Process for the preparation of 4-amino-3-chloro-5-fluoro-6- (substituted) picolinates 4--3--5--6-()-2-
IL223220A (en) A process for producing the history of extinacidine and its intermediates
ZA201305582B (en) Process for the preparation of 4-amino-5-fluoro-3-halo-6-(sunstituted)picolinates
IL226405A0 (en) Methods and compounds useful in synthesis@aminodihydrothializin@fused
EP2731429A4 (en) COMPOUNDS, METHODS OF PREPARATION AND METHODS OF USE
PL2640711T3 (pl) Ulepszony sposób otrzymywania rufinamidu
HK1187493A1 (en) Process for the preparation of 4-amino-3-chloro-5-fluoro-6- (substituted)picolinates 4--3--5--6-()-2-
SG11201406623PA (en) Process for the preparation of rivaroxaban and intermediates thereof
IL227711A0 (en) Phenyl-isoxazole history and their preparation process
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2672963A4 (en) METHOD FOR THE TREATMENT OF MELANOMA
PL3434669T3 (pl) Związki pośrednie mające zastosowanie w syntezie (-)-hupercyny i sposób otrzymywania jednego z tych związków pośrednich
ZA201207397B (en) Process for the preparation of dexlansoprazole
IL225915A0 (en) 5-trifluoromethyl-4-nitro-2-isoxazoline compounds and their preparation process
ZA201404277B (en) Process for making magnolol and derivatives thereof
PT2603319E (pt) Processo para a preparação de uretanos
PT2593423E (pt) Processo para a preparação de agentes de contraste
ZA201108148B (en) Triazine-aryl-bis-indoles and process for preparation thereof
EP2725357A4 (en) IFRET PROBE AND ITS USE
PL391702A1 (pl) Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny
PL391303A1 (pl) Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny